CeNturIOn: An open-label randomised phase II trial of ruCaparib combined with Nivolumab +/-Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian cancer
Funder: Cancer Research UKDuration: January 2020 - December 2023
People
| Name | Telephone | Office | ||
|---|---|---|---|---|
|
Professor Emmanouil Karteris Professor in Biomedical Sciences (Principal investigator)
T: +44 (0)1895 265892
E: emmanouil.karteris@brunel.ac.uk |
+44 (0)1895 265892 | emmanouil.karteris@brunel.ac.uk | Heinz Wolff 129 |